Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Lorzone, Parafon Forte DSC
Synonyms :
chlorzoxazone
Class :
Skeletal Muscle Relaxants
Brand Name :
Lorzone, Parafon Forte DSC
Synonyms :
chlorzoxazone
Class :
Skeletal Muscle Relaxants
Dosage Forms & StrengthsÂ
Tablet Â
750mgÂ
500mgÂ
375mgÂ
Administer 250 to 750mg orally thrice or four times a day
Dosage Forms & StrengthsÂ
TabletÂ
750mgÂ
500mgÂ
375mgÂ
Administer 20 mg/kg orally divided thrice or four times a day or
600 mg/m² orally divided every thrice or four times a day
Dosage Forms & StrengthsÂ
TabletÂ
750mgÂ
500mgÂ
375mgÂ
Administer 250 mg orally every 6 to 12 hours; increase the dosage to 750 mg orally whenever needed to every 6 to 8 hours
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may enhance the serum concentration of CYP3A4 inhibitors
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may enhance the serum concentration of CYP3A4 inhibitors
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
When chlorzoxazone is used together with somatotropin, this leads to a rise in chlorzoxazone’s metabolism
When encainide is used together with chlorzoxazone, this leads to a reduction in the encainide’s metabolism
When chlorzoxazone is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
When emylcamate is used together with chlorzoxazone, this leads to enhanced risk or seriousness of CNS depression
When chlorzoxazone is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with chlorzoxazone, this leads to enhanced risk or seriousness of CNS depression
chlorzoxazone leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
chlorzoxazone leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
chlorzoxazone leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
chlorzoxazone: it may increase the central nervous system depressant activities of tolperisone
chlorzoxazone may decrease the excretion rate of almasilate, leading to higher serum levels
chlorzoxazone might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
it increases the toxicity of muscle relaxants
Actions and Spectrum:Â
The mechanism of chlorzoxazone’s action is thought to involve inhibiting interneuronal activity in the brain’s spinal cord and subcortical areas.
It may exert its effects by depressing the polysynaptic pathways, inhibiting both monosynaptic and polysynaptic reflexes at the spinal level. chlorzoxazone may also act directly on skeletal muscles, causing relaxation and reducing muscle spasms.Â
chlorzoxazone primarily targets skeletal muscle spasms and is most effective in treating conditions associated with acute musculoskeletal disorders or injuries.Â
Frequency definedÂ
1-10%Â
DizzinessÂ
Excitement, ParadoxicalÂ
Angioneurotic edemaÂ
LightheadednessÂ
DrowsinessÂ
SomnolenceÂ
Rash Â
<1%(rare)Â
Hepatotoxicity Â
Anaphylaxis Â
Gastrointestinal hemorrhage
Black box warning:Â
NoneÂ
Contraindications/caution:Â
Contraindications:Â
Caution:Â
Pregnancy consideration: CÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
Central Nervous System (CNS) Effects: chlorzoxazone is thought to act on the CNS by depressing interneuronal activity in the spinal cord and subcortical brain areas. It may inhibit polysynaptic pathways and reduce monosynaptic and polysynaptic reflexes at the spinal level. Â
Muscle Relaxant Effects: chlorzoxazone is believed to affect skeletal muscle function directly. It may inhibit the release of calcium ions from the sarcoplasmic reticulum in muscle cells, thereby reducing muscle contraction and inducing muscle relaxation.Â
Pharmacodynamics:Â
chlorzoxazone is a centrally-acting muscle relaxant with pharmacodynamic effects that primarily target the central nervous system (CNS) and skeletal muscles.Â
Pharmacokinetics:Â
AbsorptionÂ
chlorzoxazone is well absorbed after oral administration. The half-life is approximately 66 minutes. The onset of action is around 1 hour. The duration of action of chlorzoxazone is typically between 6 to 12 hours. Â
DistributionÂ
The peak plasma time of chlorzoxazone occurs approximately 1 to 4 hours after administration. The peak plasma concentration ranges from 9 to 20 mcg/mL. Â
MetabolismÂ
chlorzoxazone undergoes rapid hepatic glucuronidation, which is the process of conjugating the drug with glucuronic acid in the liver to form inactive metabolites. The primary metabolite of chlorzoxazone is 6-hydroxychlorzoxazone. This metabolite is inactive and is rapidly excreted in the urine. Â
Elimination and ExcretionÂ
chlorzoxazone and its metabolites are primarily excreted in the urine.Â
Administration:Â
It is usually taken with or without food, depending on individual preference and tolerability. However, taking it with food can help minimize potential gastrointestinal side effects.Â
Patient information leafletÂ
Generic Name: chlorzoxazoneÂ
Why do we use chlorzoxazone?Â
chlorzoxazone is primarily used as a muscle relaxant to relieve muscle spasms and pain. Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
